NCT03993392View on ClinicalTrials.gov

SUBLOCADE Rapid Initiation Study

PHASE4CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

August 29, 2019

Primary Completion Date

December 26, 2019

Study Completion Date

December 26, 2019

Conditions

Opioid-use Disorder

Interventions

DRUG

TM buprenorphine

4mg TM buprenorphine, investigator choice as to brand

DRUG

SUBLOCADE

300mg subcutaneous injection

Trial Locations (1)

08009

Hassman Research Institute, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Indivior Inc.

INDUSTRY

NCT03993392 - SUBLOCADE Rapid Initiation Study | Biotech Hunter | Biotech Hunter